IPO Premiums
IPO calendar
QBListed

Q-Line Biotech Limited

Bookbuilding IPO · NSE

Price band
₹326 - ₹343
Lot size
400 shares
Issue amount
₹214.48 cr
Total subscription
102.49×
Current price₹504.35
Listing price ₹452
Watch live price ↗
Opens
21 May 2026
Closes
25 May 2026
Allotment
26 May 2026
Listing
29 May 2026

Offer at a glance

Issue overview

Issue size
62,53,200 shares
Face value
₹10 per share
Minimum investment
₹1,30,400
Fresh issue
₹214.48 cr
Offer for sale
₹0 cr
Registrar
Purva Sharegistry India Private Limited
Listing exchange
NSE
Maximum investment
₹1,37,200
Issue type
Bookbuilding IPO
Shares before issue
1,70,74,999
Shares after issue
2,33,28,199

Lot sizes

CategoryLotsSharesAmount
RETAIL2800₹2,74,400
sHNI31,200₹4,11,600
bHNI83,200₹10,97,600

Share reservation

Anchor28.48%
QIB19%
HNI14.26%
RETAIL33.25%
Market Maker5.01%

Subscription & GMP

Subscription by category

Total subscribed102.49×

Reported 25 May 2026

QIB123.94×
NIB146.33×
RETAIL71.44×
HNIs(10L+)178.82×
HNIs(2-10L)81.35×

GMP history

05711418 May: ₹4018 May: ₹018 May: ₹2219 May: ₹7919 May: ₹6819 May: ₹5719 May: ₹8820 May: ₹9120 May: ₹11320 May: ₹8520 May: ₹7920 May: ₹8021 May: ₹10621 May: ₹11422 May: ₹10222 May: ₹9925 May: ₹8325 May: ₹7025 May: ₹10625 May: ₹10225 May: ₹9225 May: ₹9726 May: ₹8826 May: ₹8526 May: ₹9727 May: ₹9727 May: ₹9327 May: ₹8827 May: ₹9328 May: ₹10528 May: ₹9828 May: ₹10228 May: ₹9329 May: ₹95
18 May₹9529 May

Day-wise demand

21 May4.11×
22 May9.86×
25 May102.49×

Application-wise demand

CategoryReserved applicationsApplied applications
QIB0197
NIB049,781
RETAIL2,5991,85,677
HNIs(10L +)49531,162
HNIs (2-10L)24818,619

Subscription demand

Amounts in ₹ crore. HNI subcategories are included in the NII total.

CategoryOfferedDemand
QIBs40.755,050.24
FIIs0711.11
FIs01,107.77
Mutual Funds094
Others03,137.37
RETAIL71.325,094.98
HNIs 2+10.19829.29
HNIs 10+20.393,645.72

Financial performance

Company financials

In Crores · Reported periods may include interim results.

Revenue & profitIn Crores
0100200300400Mar-23 · Revenue: 184.81Mar-23 · Profit after tax: 32.09Mar-23Mar-24 · Revenue: 206.45Mar-24 · Profit after tax: 34.44Mar-24Mar-25 · Revenue: 322.58Mar-25 · Profit after tax: 28.13Mar-25Dec-25 · Revenue: 236.5Dec-25 · Profit after tax: 38.69Dec-25
RevenueProfit after tax

Key performance indicators

MetricDec-25Mar-25Mar-24Mar-23
EPS23.5728.6321.8720.38
ROE16.8823.7421.2925.2
ROCE13.3217.6619.2522.14
RONW0000
PRE IPO(PE)0000
POST IPO(PE)0000

Values and labels as reported in the issue data.

Company information

Company profile

Q-Line Biotech Limited is a healthcare diagnostics company engaged in the manufacturing and supply of In-Vitro Diagnostic (IVD) products, pathology reagents, rapid test kits, and laboratory equipment for hospitals, diagnostic laboratories, and healthcare institutions across India. Established in 2010, the company focuses on affordable diagnostic solutions and operates in the medical diagnostics and healthcare consumables segment, with its proposed IPO planned for listing on the NSE EMERGE SME platform.

Strengths

  • Strong Manufacturing & R&D Capabilities: Focus on reverse engineering, innovation, and quality control supports product development.
  • Diversified Diagnostic Product Portfolio: Wide range of reagents, kits, POC devices, and diagnostic equipment reduces dependency on one segment.
  • Wide Distribution Network: Presence across all four regions in India ensures strong market reach and customer access.

Risk factors

  • Regulatory Compliance Risk: Diagnostic and healthcare products are subject to strict approvals and quality standards.
  • Dependence on Healthcare Sector Spending: Revenue linked to hospital, lab, and diagnostic industry demand.
  • High Competition in IVD Market: Faces competition from established domestic and global diagnostic companies.

Promoters

Saurabh Garg

Amita Garg

Ayush Garg

Ajay Kumar Mahanty

Abhay Agrawal

Registrar & documents

Lead manager

Hem Securities Limited, Share India Capital Services Private Limited

Registered office

298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station Lucknow, Uttar Pradesh, 226012

+91 5222435570

[email protected]Company website ↗

Frequently Asked Questions

What is Q-Line Biotech IPO GMP today?

As of today, Q-Line Biotech IPO Grey Market Premium (GMP) is reported at +₹95 per share. Based on the upper price band of ₹343, the estimated listing price is ₹438 (+27.7% expected listing gain). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.

What is the lot size and minimum investment for Q-Line Biotech IPO?

The minimum bid lot size for Q-Line Biotech IPO is 400 shares. At the cut-off price of ₹343 per share, retail investors need a minimum application amount of ₹1,37,200 per lot. Retail applicants can apply for a maximum of 1 lots (up to ₹2,00,000).

When will Q-Line Biotech IPO allotment status be announced?

The allotment status for Q-Line Biotech IPO is scheduled to be finalized on 26 May 2026. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Purva Sharegistry India Private Limited's official portal or via BSE/NSE allotment portals.

How can I check Q-Line Biotech IPO allotment status online by PAN?

To check Q-Line Biotech IPO allotment status: 1) Visit the registrar portal (Purva Sharegistry India Private Limited) or the BSE IPO allotment page. 2) Select 'Q-Line Biotech Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.

Explore More IPO Analysis & Live Tools

Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.

Regulatory Disclaimer: Grey Market Premium (GMP) is an unofficial, unregulated indicator of market sentiment and does not represent a stock exchange transaction, guarantee, or investment advice. IPO Premiums is an informational and research portal and is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before applying for any IPO.